Health care resource utilization of patients with asthma and food allergy initiating omalizumab

Background: Patients with comorbid asthma and food allergy (FA) are at increased risk of adverse outcomes for both conditions. Omalizumab, a biologic for moderate to severe persistent asthma, received recent approval for FA. Objective: We sought to compare FA-, asthma/FA-related, and all-cause healt...

Full description

Saved in:

Bibliographic Details
Main Authors:	John A. Bird, MD, Aimee M. Near, MPH, Julie Wang, MD, Arpamas Seetasith, PhD, Vincent Garmo, MPH, Stella Ko, PharmD, Xiaohui Zhao, PhD, Riddhi Doshi, PhD, Elizabeth J. Wang, MS, Sachin Gupta, MD, David M. Fleischer, MD
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Journal of Allergy and Clinical Immunology: Global
Subjects:	Food allergy asthma health care resource use health care costs omalizumab anaphylaxis
Online Access:	http://www.sciencedirect.com/science/article/pii/S277282932500092X
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Health care resource utilization of patients with asthma and food allergy initiating omalizumab

Similar Items